Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment
Maud Kamal1, Gabi Tarcic2, Sylvain Dureau3
1Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud, France.
Abstract:
It still remains to be demonstrated that using molecular profiling to guide therapy improves patient outcome in oncology. Classification of somatic variants is not straightforward, rendering treatment decisions based on variants with unknown significance (VUS) hard to implement. The oncogenic activity of VUS and mutations identified in 12 patients treated with molecularly targeted agents (MTAs) in the frame of SHIVA01 trial was assessed using Functional Annotation for Cancer Treatment (FACT). MTA response prediction was measured in vitro, blinded to the actual clinical trial results, and survival predictions according to FACT were correlated with the actual PFS of SHIVA01 patients. Patients with positive prediction had a median PFS of 5.8 months versus 1.7 months in patients with negative prediction (P < 0.05). Our results highlight the role of the functional interpretation of molecular profiles to predict MTA response.
Insights
Functional interpretation of molecular profiles using FACT accurately predicts patient response to molecularly targeted agents (MTAs) in oncology. This approach improves progression-free survival (PFS) in cancer patients receiving MTAs.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Molecular profiling guides cancer therapy, but classifying variants of unknown significance (VUS) remains challenging.
- Implementing treatment decisions based on VUS is difficult, impacting patient outcomes.
Purpose of the Study:
- To assess the oncogenic activity of VUS and mutations in patients treated with molecularly targeted agents (MTAs).
- To evaluate the predictive accuracy of the Functional Annotation for Cancer Treatment (FACT) tool for MTA response.
Main Methods:
- Assessed oncogenic activity of VUS and mutations using FACT in 12 patients from the SHIVA01 trial.
- Performed in vitro MTA response prediction blinded to clinical trial outcomes.
- Correlated FACT-based survival predictions with actual progression-free survival (PFS).
Main Results:
- Patients with positive FACT predictions showed a significantly longer median PFS (5.8 months) compared to those with negative predictions (1.7 months).
- The P-value was less than 0.05, indicating statistical significance.
Conclusions:
- Functional interpretation of molecular profiles using FACT is crucial for predicting MTA response in oncology.
- This approach can aid in optimizing cancer treatment strategies and improving patient outcomes.
Related Concept Videos
Predicting Reaction Outcomes
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Statistical Software for Data Analysis and Clinical Trials
Viral Mutations
Trial and Error and Algorithm


